Víctor Cervera-Carrascón

  • Citations Per Year
Learn More
4005. P299<lb>Phosphopeptides as novel tumor antigens in colorectal cancer<lb>Sarah A Penny, Jennifer G Abelin, Abu Z Saeed, Stacy A Malaker,<lb>Paisley T Myers, Jeffrey Shabanowitz, Stephen T Ward, Donald F<lb>Hunt, Mark Cobbold<lb>University of Birmingham, Birmingham, England, UK; University of<lb>Virginia, Charlottesville, VA, USA; Stanford University,(More)
O1 IL-15 primes an mTOR-regulated gene-expression program to prolong anti-tumor capacity of human natural killer cells Andreas Lundqvist, Vincent van Hoef, Xiaonan Zhang, Erik Wennerberg, Julie Lorent, Kristina Witt, Laia Masvidal Sanz, Shuo Liang, Shannon Murray, Ola Larsson, Rolf Kiessling, Yumeng Mao Karolinska Institutet, Stockholm, Stockholms Lan,(More)
Adoptive T-cell transfer is a promising treatment approach for metastatic cancer, but efficacy in solid tumors has only been achieved with toxic pre- and postconditioning regimens. Thus, adoptive T-cell therapies would benefit from complementary modalities that enable their full potential without excessive toxicity. We aimed to improve the efficacy and(More)
Systemic high dose interleukin-2 (IL-2) postconditioning has long been utilized in boosting the efficacy of T cells in adoptive cell therapy (ACT) of solid tumors. The resulting severe off-target toxicity of these regimens renders local production at the tumor an attractive concept with possible safety gains. We evaluated the efficacy and safety of(More)
  • 1